ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > ライセンス > BFS-21001

TIGIT-Fc protein

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: TIGIT-Fc protein
    Indications: Advanced solid tumors, especially those with high expression of CD155
    Research phase: Complete preliminary pharmacodynamic validation
    Cooperation demands: Project authorization, transfer or co-development.
  • Highlights
    1. Strong global competitiveness. Compared with the stiff competition of TIGIT mAb and bispecific antibody, TIGIT-FC fusion protein hasn’t been reported in development of oncology indications around the world, and this asset has the potential of FIC.
    2. Multi-target mechanism.
    a) TIGIT-FC can block the binding of CD155 with TIGIT and CD96, enhance the anti-tumor effect of NK cells and CD8+T cells, promote the differentiation of Naive CD4+T cells to Th1 cell, and inhibit Treg cell activity;
    b) CD155 is highly expressed in a variety of tumor cells. TIGIT-FC combined with CD155 inhibits tumor cell invasion, migration and tumor angiogenesis;
    c) IgG1, Fc subtype , mediates ADCC effect and kills tumor cells;
    d) TIGIT-Fc can block the interaction between TIGIT and Clostridium nucleosa Fap protein , and then inhibit microbial-mediated immunosuppression in tumor microenvironment.
    3. Better efficacy. Pharmacodynamics studies in vivo showed that TIGIT-FC showed superior efficacy both monotherapy and in combination with PD-1/PD-L1 compared to anti-TIGIT-mAb.


  • Project Introduction

    1. Drug type: Fusion protein

    2. Indications: Advanced solid tumors, especially those with high expression of CD155, Hepatocellular carcinoma, prostate cancer, colorectal cancer, gastric adenocarcinoma, endometrial cancer and so on.

    3. Research progress:
    a) The proof of concept that TIGIT-Fc can promote anti-tumor immunity was completed;
    b) The tumor activity of TIGIT-Fc antibody was preliminarily verified in the tumor mouse model of CT26 and MC38;
    c) In CT26 and MC38 tumor mouse models, it was preliminarily verified that the combination of TIGIT-Fc and anti-PD-L1 can improve the anti-tumor efficacy.

Comments (0)

お問い合わせ

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments